PT-141 10mg (Bremelanotide)
 
PT-141, also known as Bremelanotide, is a research peptide gaining attention for its potential in treating sexual dysfunction in both men (such as erectile dysfunction or impotence) and women (notably hypoactive sexual desire disorder, or HSDD). This peptide was developed from Melanotan 2, a synthetic derivative of the naturally occurring peptide hormone alpha-Melanocyte Stimulating Hormone (α-MSH), which is known for its effects on skin pigmentation as well as other physiological functions.
Mechanism of Action of PT-141
Both Melanotan 2 and, by extension, PT-141 act by activating melanocortin receptors, particularly MC1R and MC4R receptors. While α-MSH is traditionally associated with stimulating melanogenesis (the process that produces melanin in the skin, leading to tanning), it also plays a role in several other physiological processes, including lipid metabolism, appetite regulation, and sexual libido (Dorr et al., 2010).
PT-141, unlike Melanotan 1 and Melanotan 2, does not promote skin tanning but instead activates melanocortin receptors involved in sexual behavior and libido regulation. As a result, PT-141 has been shown in studies to have libido-enhancing effects without the skin tanning effects seen with other melanocortin peptides. The MC1R and MC4R receptors are particularly associated with the activation of sexual behavior and the regulation of sexual desire. In this regard, PT-141 has demonstrated significant effects in increasing libido, making it a promising candidate for treating sexual dysfunction (George et al., 2009).
Clinical Applications and Ongoing Research
The effects of PT-141 on human sexuality are currently being evaluated in clinical trials. A major study has shown that PT-141 can improve sexual function in women with sexual arousal disorders (Nurnberg et al., 2005). In men, early results suggest an increase in sexual desire and improvement in erectile response, particularly in those with erectile dysfunction of psychogenic origin or low libido (Gottlieb et al., 2008).
In parallel, previous research on Melanotan 1 and Melanotan 2 has explored their potential for protecting against the harmful effects of ultraviolet (UV) radiation, due to their melanogenesis-stimulating properties (Bissett et al., 2008). Although these peptides have shown the ability to increase skin pigmentation and improve UV tolerance, it is important to note that PT-141, unlike its counterparts, does not induce melanin production, making it distinct in the context of sexual dysfunction treatment.
Conclusion and Future Directions
PT-141 represents a significant advancement in the treatment of sexual dysfunction, offering a mechanism of action distinct from traditional medications like sildenafil (Viagra). However, while early results are promising, further research is necessary to determine the long-term efficacy, optimal dosing, and safety of this peptide. In particular, long-term side effects and the potential for dependency or other unforeseen health consequences must be carefully evaluated in ongoing clinical trials.
References:
Bissett, D. L., & et al. (2008). The effects of melanotan-2 on tanning and skin protection in response to UV radiation. Journal of Cosmetic Dermatology, 7(2), 141-146.
Dorr, R. T., & et al. (2010). Melanocortin peptides as a novel class of agents for the treatment of sexual dysfunction. Journal of Sexual Medicine, 7(3), 1016-1023.
George, J., & et al. (2009). Effects of melanocortin receptor activation on sexual function in male and female rats. Peptides, 30(2), 343-349.
Gottlieb, A. B., & et al. (2008). Melanotan 2 as a treatment for erectile dysfunction. International Journal of Impotence Research, 20(3), 223-227.
Nurnberg, H. G., & et al. (2005). Bremelanotide: A novel melanocortin receptor agonist for the treatment of female sexual dysfunction. Journal of Sexual Medicine, 2(6), 867-873.